KR20170036450A - A composition for inhibiting the growth of bacteria comprising lysozyme and organic acids - Google Patents
A composition for inhibiting the growth of bacteria comprising lysozyme and organic acids Download PDFInfo
- Publication number
- KR20170036450A KR20170036450A KR1020150135618A KR20150135618A KR20170036450A KR 20170036450 A KR20170036450 A KR 20170036450A KR 1020150135618 A KR1020150135618 A KR 1020150135618A KR 20150135618 A KR20150135618 A KR 20150135618A KR 20170036450 A KR20170036450 A KR 20170036450A
- Authority
- KR
- South Korea
- Prior art keywords
- lysozyme
- gum
- acid
- organic acid
- food preservative
- Prior art date
Links
- 102000016943 Muramidase Human genes 0.000 title claims abstract description 60
- 108010014251 Muramidase Proteins 0.000 title claims abstract description 60
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 title claims abstract description 60
- 239000004325 lysozyme Substances 0.000 title claims abstract description 60
- 235000010335 lysozyme Nutrition 0.000 title claims abstract description 60
- 229960000274 lysozyme Drugs 0.000 title claims abstract description 60
- 150000007524 organic acids Chemical class 0.000 title claims abstract description 54
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 230000002401 inhibitory effect Effects 0.000 title claims description 34
- 241000894006 Bacteria Species 0.000 title claims description 17
- 235000005985 organic acids Nutrition 0.000 title description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 66
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 59
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 44
- 239000004310 lactic acid Substances 0.000 claims description 22
- 235000014655 lactic acid Nutrition 0.000 claims description 22
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 18
- 241000186779 Listeria monocytogenes Species 0.000 claims description 18
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 18
- 239000001630 malic acid Substances 0.000 claims description 18
- 235000011090 malic acid Nutrition 0.000 claims description 18
- 235000019249 food preservative Nutrition 0.000 claims description 16
- 239000005452 food preservative Substances 0.000 claims description 16
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 15
- 239000012871 anti-fungal composition Substances 0.000 claims description 12
- 235000015165 citric acid Nutrition 0.000 claims description 11
- 235000011054 acetic acid Nutrition 0.000 claims description 10
- 230000002538 fungal effect Effects 0.000 claims description 7
- 229920000591 gum Polymers 0.000 claims description 6
- 229920000858 Cyclodextrin Polymers 0.000 claims description 4
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 claims description 2
- 244000215068 Acacia senegal Species 0.000 claims description 2
- 239000001904 Arabinogalactan Substances 0.000 claims description 2
- 229920000189 Arabinogalactan Polymers 0.000 claims description 2
- 102000011632 Caseins Human genes 0.000 claims description 2
- 108010076119 Caseins Proteins 0.000 claims description 2
- 229920002101 Chitin Polymers 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229920002148 Gellan gum Polymers 0.000 claims description 2
- 229920002907 Guar gum Polymers 0.000 claims description 2
- 229920000084 Gum arabic Polymers 0.000 claims description 2
- 229920000161 Locust bean gum Polymers 0.000 claims description 2
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 claims description 2
- 229920001100 Polydextrose Polymers 0.000 claims description 2
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 claims description 2
- 240000004584 Tamarindus indica Species 0.000 claims description 2
- 235000004298 Tamarindus indica Nutrition 0.000 claims description 2
- 229920001615 Tragacanth Polymers 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 239000000205 acacia gum Substances 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- 235000019312 arabinogalactan Nutrition 0.000 claims description 2
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 claims description 2
- 235000010418 carrageenan Nutrition 0.000 claims description 2
- 239000000679 carrageenan Substances 0.000 claims description 2
- 229920001525 carrageenan Polymers 0.000 claims description 2
- 229940113118 carrageenan Drugs 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 235000010492 gellan gum Nutrition 0.000 claims description 2
- 239000000216 gellan gum Substances 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 235000010420 locust bean gum Nutrition 0.000 claims description 2
- 239000000711 locust bean gum Substances 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 235000013856 polydextrose Nutrition 0.000 claims description 2
- 239000001259 polydextrose Substances 0.000 claims description 2
- 229940035035 polydextrose Drugs 0.000 claims description 2
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 claims description 2
- 239000000770 propane-1,2-diol alginate Substances 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 229940080237 sodium caseinate Drugs 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 4
- 229930195712 glutamate Natural products 0.000 claims 4
- 241000416162 Astragalus gummifer Species 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- 229920002558 Curdlan Polymers 0.000 claims 1
- 239000001879 Curdlan Substances 0.000 claims 1
- 229920000569 Gum karaya Polymers 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 241000934878 Sterculia Species 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 229940045110 chitosan Drugs 0.000 claims 1
- 235000019316 curdlan Nutrition 0.000 claims 1
- 229940078035 curdlan Drugs 0.000 claims 1
- 235000010494 karaya gum Nutrition 0.000 claims 1
- 239000000231 karaya gum Substances 0.000 claims 1
- 229940039371 karaya gum Drugs 0.000 claims 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 229940032147 starch Drugs 0.000 claims 1
- 235000010491 tara gum Nutrition 0.000 claims 1
- 239000000213 tara gum Substances 0.000 claims 1
- 235000010487 tragacanth Nutrition 0.000 claims 1
- 239000000196 tragacanth Substances 0.000 claims 1
- 229940116362 tragacanth Drugs 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 10
- 230000035755 proliferation Effects 0.000 abstract description 3
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 230000000845 anti-microbial effect Effects 0.000 description 16
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 13
- 235000013305 food Nutrition 0.000 description 13
- 239000000243 solution Substances 0.000 description 10
- 206010016952 Food poisoning Diseases 0.000 description 9
- 208000019331 Foodborne disease Diseases 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 230000000813 microbial effect Effects 0.000 description 6
- 238000010610 time kill assay Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000001384 succinic acid Substances 0.000 description 5
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 4
- 108010053775 Nisin Proteins 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000004309 nisin Substances 0.000 description 4
- 235000010297 nisin Nutrition 0.000 description 4
- 238000005259 measurement Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 206010027202 Meningitis bacterial Diseases 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 201000009904 bacterial meningitis Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000004020 Brain Abscess Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010058780 Meningitis neonatal Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 201000009840 acute diarrhea Diseases 0.000 description 1
- 208000012873 acute gastroenteritis Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000420 anogeissus latifolia wall. gum Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 235000019314 gum ghatti Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2462—Lysozyme (3.2.1.17)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/10—Preserving against microbes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
The present invention relates to a fungal growth inhibiting composition comprising lysozyme and an organic acid, and more particularly to a fungal growth inhibiting composition having a stronger antimicrobial activity by using a mixture of lysozyme and an organic acid.
Listeria monocytogenes is a gram-positive anaerobic anaerobic bacillus, the flagella are predominant and the optimum temperature is 30 to 37 ° C. However, it can grow at refrigeration and freezing temperatures, and can survive for a relatively long time under dry conditions, resulting in infectious food poisoning.
The Listeria monocytogenes causes bacterial meningitis, and is also a bacterium with a mortality rate of 22%. It is also one of the three major causative agents of neonatal meningitis and is the most common bacterial meningitis in patients with immunosuppression due to lymphoma, organ transplantation, and steroids. In addition, it can cause other brain meningitis, brain abscess, endocarditis, and local infection. In recent studies, it has been reported that acute gastroenteritis can be induced in a group and cause acute diarrhea in normal people.
However, in healthy people, symptoms do not appear or symptoms of mild food poisoning are manifested. However, if a susceptible pregnant woman and a newborn infant with weak immunity, an elderly person, diabetes, epilepsy, chronic kidney disease and iron- The probability of disease occurrence increases. In addition, listeric meningitis is associated with a mortality rate of about 70%, sepsis 50%, and pregnant women or newborns 80%.
The Listeria monocytogenes has recently been attracted by large-scale food poisoning incidents in the United States and the increased risk of food poisoning caused by the bacteria as the consumption of simple cooked food to eat without cooking increases.
Lysozyme has been recognized for its excellent antibacterial and safety properties and is widely used as a natural antimicrobial agent and food preservative in foods, agricultural, livestock and pharmaceuticals.
The lysozyme is colorless, tasteless, and odorless. However, the lysozyme has been widely applied to food, but its antibacterial spectrum is narrow and its price competitiveness is low. Thus, studies using lysozyme have been conducted by mixing with EDTA and nisin.
However, the mixture of lysozyme and EDTA lowers the pH of the food, and nisin raises the cost.
Therefore, it is necessary to study the new antimicrobial substance against food harmful microorganisms such as food poisoning bacteria including Listeria monocytogenes which is harmless to human body and excellent in price competitiveness.
It is an object of the present invention to provide a composition comprising lysozyme and an organic acid capable of inhibiting the growth of bacteria.
It is another object of the present invention to provide a food preservative containing the composition to inhibit the growth of bacteria in food.
In order to achieve the above object,
The present invention provides a fungal growth inhibiting composition comprising lysozyme and an organic acid.
In addition, the present invention provides a food preservative containing the microbial growth inhibiting composition.
The fungal growth inhibiting composition of the present invention can have a higher antibacterial effect by using lysozyme and organic acid together.
Further, the bactericidal growth inhibiting composition of the present invention is water-soluble, stable, and can be used as a food preservative.
1 shows a checkerboard method.
2 is a flow chart illustrating a time-kill assay method.
FIG. 3 is a graph showing the antimicrobial synergy effect of lysozyme and acetic acid (AA) on Listeria monocytogenes KCTC 3710, as measured by the time-kill assay method.
FIG. 4 is a graph showing the antimicrobial synergy effect of lysozyme and citric acid (CA) on Listeria monocytogenes KCTC 3710, as measured by the time-kill assay method.
FIG. 5 is a graph showing the antimicrobial synergy effect of lysozyme and lactic acid (LA) on Listeria monocytogenes KCTC 3710, as measured by the time-kill assay method.
FIG. 6 is a graph showing the antimicrobial synergy effect of lysozyme and malic acid (MA) on Listeria monocytogenes KCTC 3710, as measured by the time-kill assay method.
FIG. 7 is a graph showing the antimicrobial synergy effect of lysozyme and succinic acid (SA) on Listeria monocytogenes KCTC 3710, measured by the time-kill assay method.
Hereinafter, the present invention will be described in more detail.
The present invention relates to a fungal growth inhibiting composition comprising lysozyme and an organic acid.
Lysozyme is a substance with excellent antibacterial activity and is used for natural antimicrobial agents and food preservatives. However, since the lysozyme is dependent on the import, there is a problem that the cost is high.
In order to solve the above problems, EDTA or nisin has been used together with lysozyme. However, when EDTA is used together, the pH is low and can not be used in food preservatives and the like, and when the nisin is used together, the cost increases and the economical cost problem can not be solved.
Therefore, in the present invention, organic acids are used together with lysozyme to solve the above problems.
The use of the organic acid together can reduce the amount of lysozyme used, which can reduce the economic cost, and the antimicrobial activity of the lysozyme can be increased, so that the antifungal composition having higher antimicrobial activity can be provided.
The use of organic acids in combination with lysozyme also improves the antimicrobial activity.
Preferably, the organic acid is selected from the group consisting of malic acid (MA), lactic acid (LA), citric acid, citric acid, CA), succinic acid (SA), and acetic acid (AA).
The lysozyme and the organic acid are mixed at a weight ratio of 10: 1 to 80: 1, preferably 20: 1 to 40: 1.
When the lysozyme and the organic acid are mixed at a weight ratio of 10: 1 to 80: 1, excellent antibacterial activity can be exhibited.
In addition, the microbial growth inhibiting composition of the present invention does not particularly limit the kind of the microorganism, but preferably inhibits the proliferation of Listeria monocytogenes.
The Listeria monocytogenes is a bacterium that causes food poisoning, and is capable of proliferating at refrigeration and freezing temperatures, further increasing the risk of food poisoning.
The fungus growth inhibiting composition comprising lysozyme and organic acid of the present invention is excellent in antibacterial activity against the Listeria monocytogenes and can prevent food poisoning.
In addition, the antifungal composition of the present invention has a pH of 5 to 7, and preferably a pH of 6 to 7. If the pH is low, it is difficult to grow the microorganism and may cause a change in the food. However, since the pH of the mycelial growth inhibiting composition of the present invention is in the above range, the growth of bacteria can be suppressed without affecting the food.
The present invention also relates to a food preservative comprising the microbial growth inhibiting composition comprising the lysozyme and the organic acid of the present invention.
The antifungal composition of the present invention is water-soluble, stable, and can be used as a food preservative because it does not change food when added to food, thereby preventing diseases caused by bacteria.
More specifically, the antifungal composition of the present invention is excellent in antimicrobial activity against L. monocytogenes, so that the proliferation of the bacteria can be inhibited and food poisoning and the like can be prevented.
In addition, a thickener and a stabilizer can be added to the food preservative as a food additive, and examples thereof include methylcellulose, ethylcellulose, carboxymethylcellulose sodium, carboxymethylcellulose calcium, carboxymethylstarch sodium, propylene glycol alginate, But are not limited to, sodium, sodium caseinate, sodium alginate, polydextrose, modified starch, hydroxypropylmethylcellulose, guar gum, locust bean gum, xanthan gum, gum arabic, alginic acid, gelatin, gellan gum, carrageenan, , Tamarind gum, tragacanth gum, pectin, glucomannan, ghatti gum, microfibrous cellulose, silicate seed gum, arabinogalactan, chitin, persellaran, dhamma gum, dextrin, cyclodextrin and cyclodextrin syrup And at least one selected from the group consisting of The food preservative can be prepared in powder form by including these materials.
Hereinafter, the present invention will be described in more detail by way of examples. However, the following examples are intended to further illustrate the present invention, and the scope of the present invention is not limited by the following examples.
Comparative Example One. Lysozyme Minimum inhibitory concentration ( MIC ) Measure
Lysozyme (Lyz) was dissolved in a 0.1 M sodium phosphate buffer solution (pH 6.0) to prepare a 0.014 M lysozyme solution.
100 μL of the lysozyme solution was added to a sterile 96-well plate (SPL life science, Pocheon, Korea) containing 100 μL of BHI broth (Oxoid Ltd., Basingstoke, England), and L. monocytogenes KCTC 3710 7 log CFU / mL and incubated at 37 DEG C for 24 hours.
The above-mentioned L. monocytogenes KCTC 3710 was purchased from the Korean Collection for Type Cultures (KCTC) of the Korea Research Institute of Bioscience and Biotechnology.
The 96-well plate immediately after the inoculation of the strain and incubated for 24 hours was measured for absorbance at 600 nm using an enzyme-linked immunosorbent assay (ELISA) reader (SpectraMax M2e, Molecular Devices, CA, USA) Minimal inhibitory concentrations (MIC) of lysozyme were set, and the results are shown in Table 1 below.
Comparative Example 2. Minimum inhibitory concentration of organic acids ( MIC ) Measure
Lactic acid (LA), citric acid (CA), succinic acid (SA) and acetic acid (AA) were used as organic acid (OA) .
The organic acid was dissolved in distilled water to prepare 0.33 M acetic acid solution, 0.1 M citric acid solution, 0.15 M lactic acid solution, 0.22 M malic acid solution and 0.17 M succinic acid solution.
Minimal inhibitory concentrations (MIC) of organic acids were measured in the same manner as in Comparative Example 1 except that an organic acid solution was used in place of the lysozyme solution of Comparative Example 1, and the results are shown in Table 1 below .
Example 1. Antimicrobial activity measurement by Checkerboard method
A sterile 96-well plate (SPL life science, Pocheon, Korea) containing 100 μL of BHI broth (Oxoid Ltd., Basingstoke, England) was prepared.
On the horizontal axis, the minimum inhibitory concentration of organic acids in Table 1 was increased from 1/32 to 2 times, and then 50 μL was added up to 8 times. On the vertical axis, the minimum inhibitory concentration of lysozyme was increased from 1/32 to 2 times 50 [mu] L was added up to 4 times so that the total volume became 200 [mu] L (Fig. 1).
L. monocytogenes KCTC 3710 was inoculated to a medium containing the lysozyme and an organic acid at 7 log CFU / mL and incubated at 37 ° C. for 24 hours. Minimal inhibitory concentrations (MIC) , And the fractional inhibitory concentration index (FICI) was calculated by the following
[Equation 1]
In addition, the FICI value
If FICI ≤ 0.5, synergy,
If 0.5 <FICI ≤ 1, additive,
If 1 <FICI ≤ 2, then indifference,
2 < FICI.
From the results shown in the above Table 2, it was confirmed that the minimum inhibitory concentration of lysozyme was at least 40-fold reduced in a composition in which malic acid (MA), citric acid (CA) and acetic acid (AA) were mixed with lysozyme.
In addition, it was confirmed that the minimum inhibitory concentration of lysozyme was at least 20 times lower in a composition in which lactic acid (LA) and succinic acid (SA) were mixed with lysozyme, respectively.
In addition, the minimum inhibitory concentration of lysozyme decreased as the concentration of organic acid increased.
Therefore, it can be seen that the microbial growth inhibiting composition comprising lysozyme and organic acid of the present invention exhibits higher antimicrobial activity by including both substances together.
It can be seen from the results in Table 3 that lysozyme (Lyz) has a synergistic effect with organic acids such as acetic acid (AA), citric acid (CA), lactic acid (LA), malic acid (MA) and succinic acid (SA).
That is, the antifungal composition containing lysozyme and organic acid of the present invention has higher antibacterial activity than lysozyme alone.
Example 2. Measurement of antimicrobial activity by time kill curve method
Lysosyme (Lyz) was used 0.25 times and 0.5 times the minimum inhibitory concentration and malic acid (MA), lactic acid (LA), citric acid (CA) as organic acid ), Succinic acid (SA) and acetic acid (AA) were used, and the two materials were mixed using 0.25 times and 0.5 times of the minimum inhibitory concentration.
The L. monocytogenes KCTC 3710 in the
After culturing the bacterium on the BHI agar for 24 hours at 37 ° C, the number of bacteria was measured to obtain an average value (FIG. 2).
When the number of bacteria is decreased by 2 log CFU / mL or more, synergy (S) decreases by 2 log CFU / mL or less, or by 2 log CFU / mL or more when the lysozyme is used alone. ).
The measurement results are shown in Table 4 below.
In the results of Table 4, the antimicrobial activity of acetic acid (AA), citric acid (CA) and lactic acid (LA) was increased when lysozyme or organic acid was used alone with lysozyme (Figs. 3 to 5) (MA) and succinic acid (SA), when used together with lysozyme, significantly increased the antimicrobial activity compared to lysozyme or organic acid alone (FIGS. 6 and 7).
Therefore, it has been found that the microbial growth inhibiting composition comprising lysozyme and organic acid of the present invention has better antibacterial activity than when lysozyme or organic acid is used alone.
The pH of the fungal growth inhibiting composition containing lysozyme and organic acid was measured, and the results are shown in Table 5 below.
In the results of Table 5, the pH of the antifungal composition containing lysozyme and organic acid was slightly acidic or neutral to about 6.
This means that at a pH that does not affect the food, the antifungal composition of the present invention can inhibit the growth of bacteria in the food without affecting the food.
That is, the microbial growth inhibiting composition comprising lysozyme and organic acid of the present invention means that it can be used as a food preservative.
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150135618A KR20170036450A (en) | 2015-09-24 | 2015-09-24 | A composition for inhibiting the growth of bacteria comprising lysozyme and organic acids |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150135618A KR20170036450A (en) | 2015-09-24 | 2015-09-24 | A composition for inhibiting the growth of bacteria comprising lysozyme and organic acids |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20170036450A true KR20170036450A (en) | 2017-04-03 |
Family
ID=58588963
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020150135618A KR20170036450A (en) | 2015-09-24 | 2015-09-24 | A composition for inhibiting the growth of bacteria comprising lysozyme and organic acids |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20170036450A (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005000133A (en) * | 2003-06-16 | 2005-01-06 | Pharmafoods Kenkyusho:Kk | Egg white peptide-blended storage duration improver for food |
JP3928064B2 (en) * | 2001-03-08 | 2007-06-13 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Food additive composition |
-
2015
- 2015-09-24 KR KR1020150135618A patent/KR20170036450A/en active Search and Examination
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3928064B2 (en) * | 2001-03-08 | 2007-06-13 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Food additive composition |
JP2005000133A (en) * | 2003-06-16 | 2005-01-06 | Pharmafoods Kenkyusho:Kk | Egg white peptide-blended storage duration improver for food |
Non-Patent Citations (1)
Title |
---|
일본 특허공보 특허 제 3928064호(2007.06.13.) 1부. * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101770902B1 (en) | Method of producing partially purified extracellular metabolite products from bacillus coagulans and biological applications thereof | |
Arqués et al. | Combined effect of reuterin and lactic acid bacteria bacteriocins on the inactivation of food-borne pathogens in milk | |
CN110016442A (en) | The application of Lactobacillus rhamnosus and its composite bacterium powder in prevention and treatment vaginitis product | |
KR101594446B1 (en) | Bacillus subtilis RX7 strain having antimicrobial activity against harmful microorganism and uses thereof | |
US10487112B2 (en) | Pediococcus acidilactici derived antimicrobial hexapeptide and preparation method thereof | |
WO2006009394A1 (en) | Natural antibiotic and composition comprising thereof | |
CN1864557A (en) | Synergistic antimicrobial system | |
EP0374823B1 (en) | Control of microbial growth with nisin/lysozyme formulations | |
Del Olmo et al. | Effect of lactoferrin and its derivatives against gram-positive bacteria in vitro and, combined with high pressure, in chicken breast fillets | |
CN110916049A (en) | Noodle preservative and preparation method thereof | |
CN104970086A (en) | Biological preservative and preparation method and application thereof | |
Oh et al. | Synergistic antilisterial effects of mixtures of lysozyme and organic acids | |
CN107821439A (en) | A kind of composition for preventing and treating rice sheath blight disease and preparation method thereof | |
KR20170036450A (en) | A composition for inhibiting the growth of bacteria comprising lysozyme and organic acids | |
CN102010884B (en) | Antibacterial active matter as well as preparation method and application thereof | |
EP1481666B1 (en) | A composition for re-establishment of the vaginal ecosystem | |
CN116236466A (en) | Application of hinokitiol composition in preparation of staphylococcus aureus inhibitor | |
CN113115893B (en) | Food antibacterial additive and application thereof | |
CN113980870A (en) | Cryrogesterophilus halophilus and application thereof in refrigeration and preservation of vegetables | |
CN112602719B (en) | Antibacterial composition and application thereof | |
KR101706842B1 (en) | Bop-Sikhae and Manufacturing Method Thereof | |
Alamer et al. | Inhibitory Effect of Natural Honey on The Growth of Rhizopus stolonifer, Mucor spp., and Aspergillus niger | |
CN107712550A (en) | A kind of food antiseptic agent prescription | |
CN115969752B (en) | Application of soapberry fermentation product in regulating skin microecological balance | |
Oguz et al. | In vitro activity of sodium benzoate against clinically relevant Enterococcus faecalis and Enterococcus faecium isolates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment |